Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)’s share price fell 2.4% during trading on Thursday . The company traded as low as $1.97 and last traded at $2.02, with a volume of 529,921 shares changing hands. The stock had previously closed at $2.07.

A number of brokerages have recently commented on MRNS. Jefferies Group reaffirmed a “buy” rating and issued a $2.50 target price (down from $13.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, June 14th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, May 3rd. Stifel Nicolaus reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, June 28th. Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 7th. Finally, Royal Bank Of Canada cut shares of Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $14.00 to $2.00 in a report on Tuesday, June 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Marinus Pharmaceuticals has an average rating of “Hold” and a consensus target price of $7.80.

The stock’s 50-day moving average is $2.38 and its 200 day moving average is $4.62. The stock’s market cap is $39.41 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities analysts anticipate that Marinus Pharmaceuticals Inc. will post ($1.47) earnings per share for the current fiscal year.

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.